Academic Journal
أعرض في EDS

A1.79 A preliminary algorithm introducing immunogenicity assessment in the management of RA patients receiving biotechnological therapies

التفاصيل البيبلوغرافية
العنوان: A1.79 A preliminary algorithm introducing immunogenicity assessment in the management of RA patients receiving biotechnological therapies
المؤلفون: Garcês, S, Antunes, M, Benito-Garcia, E, Canas-Silva, J, Aarden, L, Demengeot, J
بيانات النشر: BMJ Publishing Group Ltd
سنة النشر: 2014
المجموعة: HighWire Press (Stanford University)
مصطلحات موضوعية: 1. Rheumatoid arthritis
الوصف: Background Clinical remission is today the treatment goal for Rheumatoid Arthritis (RA), which requires fast and assertive therapeutic decisions for a tight control of disease activity. Few objective parameters are available to guide clinical decisions, namely in switcher patients. We designed a preliminary algorithm introducing immunogenicity assessment in the current approach to RA patients receiving biotechnologic therapies. Objectives To evaluate the concordance between the new algorithm and current clinical practice, comparing the effectiveness of “immunogenicity-based” versus “empirical-based” switches in a cohort of patients with established RA receiving biologics. Methods: EULAR therapeutic response was evaluated in 105 RA patients (naive or switchers) over one year, through GEE analysis. Serum drug trough levels were assessed by ELISA and anti-drug antibodies (ADAb) by Bridging ELISA. Results During follow-up, 48.6% of patients (Group A) had concordant therapeutic decisions. One year after the therapeutic decision, patients from Group A had a higher probability of achieving response (OR = 7.91, p <0.001, 95% CI = 3.27–19.13) and low disease activity (OR = 9.77, p <0.001, 95% CI = 4.69–20.37). Non-responders to a TNFi in the presence of detectable serum drug trough levels and no detectable ADAb had higher probability of achieving response by switching to a drug with different MOA, rather than another TNFi, even after adjusting for potential confounders, such as DAS28 at the time of switch (OR = 6.76, p = 0.004, 95% CI = 1.82–25.04). Conclusions Immunogenicity assessment might help to optimise therapeutic decisions, leading to a better control of disease activity with significant better clinical outcomes in RA patients receiving biotechnologic therapies.
نوع الوثيقة: text
وصف الملف: text/html
اللغة: English
Relation: http://ard.bmj.com/cgi/content/short/73/Suppl_1/A35-a; http://dx.doi.org/10.1136/annrheumdis-2013-205124.78
DOI: 10.1136/annrheumdis-2013-205124.78
الاتاحة: http://ard.bmj.com/cgi/content/short/73/Suppl_1/A35-a
https://doi.org/10.1136/annrheumdis-2013-205124.78
Rights: Copyright (C) 2014, BMJ Publishing Group Ltd
رقم الانضمام: edsbas.19C13F0
قاعدة البيانات: BASE
ResultId 1
Header edsbas
BASE
edsbas.19C13F0
848
3
Academic Journal
academicJournal
848.219055175781
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.19C13F0&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => http://ard.bmj.com/cgi/content/short/73/Suppl_1/A35-a# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => A1.79 A preliminary algorithm introducing immunogenicity assessment in the management of RA patients receiving biotechnological therapies )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Garc&#234;s%2C+S%22&quot;&gt;Garc&#234;s, S&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Antunes%2C+M%22&quot;&gt;Antunes, M&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Benito-Garcia%2C+E%22&quot;&gt;Benito-Garcia, E&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Canas-Silva%2C+J%22&quot;&gt;Canas-Silva, J&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Aarden%2C+L%22&quot;&gt;Aarden, L&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Demengeot%2C+J%22&quot;&gt;Demengeot, J&lt;/searchLink&gt; )
Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => BMJ Publishing Group Ltd )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2014 )
Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => HighWire Press (Stanford University) )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%221%2E+Rheumatoid+arthritis%22&quot;&gt;1. Rheumatoid arthritis&lt;/searchLink&gt; )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background Clinical remission is today the treatment goal for Rheumatoid Arthritis (RA), which requires fast and assertive therapeutic decisions for a tight control of disease activity. Few objective parameters are available to guide clinical decisions, namely in switcher patients. We designed a preliminary algorithm introducing immunogenicity assessment in the current approach to RA patients receiving biotechnologic therapies. Objectives To evaluate the concordance between the new algorithm and current clinical practice, comparing the effectiveness of “immunogenicity-based” versus “empirical-based” switches in a cohort of patients with established RA receiving biologics. Methods: EULAR therapeutic response was evaluated in 105 RA patients (naive or switchers) over one year, through GEE analysis. Serum drug trough levels were assessed by ELISA and anti-drug antibodies (ADAb) by Bridging ELISA. Results During follow-up, 48.6% of patients (Group A) had concordant therapeutic decisions. One year after the therapeutic decision, patients from Group A had a higher probability of achieving response (OR = 7.91, p &lt;0.001, 95% CI = 3.27–19.13) and low disease activity (OR = 9.77, p &lt;0.001, 95% CI = 4.69–20.37). Non-responders to a TNFi in the presence of detectable serum drug trough levels and no detectable ADAb had higher probability of achieving response by switching to a drug with different MOA, rather than another TNFi, even after adjusting for potential confounders, such as DAS28 at the time of switch (OR = 6.76, p = 0.004, 95% CI = 1.82–25.04). Conclusions Immunogenicity assessment might help to optimise therapeutic decisions, leading to a better control of disease activity with significant better clinical outcomes in RA patients receiving biotechnologic therapies. )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => text )
Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => text/html )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => http://ard.bmj.com/cgi/content/short/73/Suppl_1/A35-a; http://dx.doi.org/10.1136/annrheumdis-2013-205124.78 )
Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1136/annrheumdis-2013-205124.78 )
Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => http://ard.bmj.com/cgi/content/short/73/Suppl_1/A35-a&lt;br /&gt;https://doi.org/10.1136/annrheumdis-2013-205124.78 )
Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => Copyright (C) 2014, BMJ Publishing Group Ltd )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.19C13F0 )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1136/annrheumdis-2013-205124.78 ) ) [Languages] => Array ( [0] => Array ( [Text] => English ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => 1. Rheumatoid arthritis [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => A1.79 A preliminary algorithm introducing immunogenicity assessment in the management of RA patients receiving biotechnological therapies [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Garcês, S ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Antunes, M ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Benito-Garcia, E ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Canas-Silva, J ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Aarden, L ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Demengeot, J ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 01 [Type] => published [Y] => 2014 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-locals [Value] => edsbas ) [1] => Array ( [Type] => issn-locals [Value] => edsbas.oa ) ) ) ) ) ) )
IllustrationInfo